JP2021514368A5 - - Google Patents

Download PDF

Info

Publication number
JP2021514368A5
JP2021514368A5 JP2020543999A JP2020543999A JP2021514368A5 JP 2021514368 A5 JP2021514368 A5 JP 2021514368A5 JP 2020543999 A JP2020543999 A JP 2020543999A JP 2020543999 A JP2020543999 A JP 2020543999A JP 2021514368 A5 JP2021514368 A5 JP 2021514368A5
Authority
JP
Japan
Prior art keywords
ligand
nucleic acid
treatment
stem cell
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543999A
Other languages
English (en)
Japanese (ja)
Other versions
JP7278296B2 (ja
JP2021514368A (ja
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Priority claimed from US16/269,572 external-priority patent/US11655293B2/en
Application filed filed Critical
Publication of JP2021514368A publication Critical patent/JP2021514368A/ja
Publication of JP2021514368A5 publication Critical patent/JP2021514368A5/ja
Application granted granted Critical
Publication of JP7278296B2 publication Critical patent/JP7278296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543999A 2018-02-22 2019-02-22 Allo-HCTを受けた患者の血液悪性腫瘍の治療に使用するためのGM-CSFまたはGM-CSF受容体のリガンド Active JP7278296B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16/269,572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (3)

Publication Number Publication Date
JP2021514368A JP2021514368A (ja) 2021-06-10
JP2021514368A5 true JP2021514368A5 (cg-RX-API-DMAC7.html) 2021-10-21
JP7278296B2 JP7278296B2 (ja) 2023-05-19

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543999A Active JP7278296B2 (ja) 2018-02-22 2019-02-22 Allo-HCTを受けた患者の血液悪性腫瘍の治療に使用するためのGM-CSFまたはGM-CSF受容体のリガンド

Country Status (11)

Country Link
US (3) US11655293B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755715A1 (cg-RX-API-DMAC7.html)
JP (1) JP7278296B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200123434A (cg-RX-API-DMAC7.html)
CN (1) CN111886248B (cg-RX-API-DMAC7.html)
AU (1) AU2019224550A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091536A1 (cg-RX-API-DMAC7.html)
MA (1) MA51893A (cg-RX-API-DMAC7.html)
MX (2) MX2020008792A (cg-RX-API-DMAC7.html)
WO (1) WO2019162472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
TW202317637A (zh) * 2021-08-26 2023-05-01 日商協和麒麟股份有限公司 與cd116及cd131結合之雙特異性抗體

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009772A (pt) 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
ES2918209T3 (es) 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Gm-csf 수용체에 대한 결합 성분
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
BR112013033944A2 (pt) * 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性t細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Similar Documents

Publication Publication Date Title
US12054557B2 (en) Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer
JP2022188225A (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
Skorka et al. The application of CAR-T cells in haematological malignancies
US20170174781A1 (en) Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
Nair-Gupta et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia
US20250304701A1 (en) Nk engager molecules and methods of use thereof
KR20180110141A (ko) 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합
Hashem Boroojerdi et al. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
Wei et al. Chimeric antigen receptor T-cell therapy for T-ALL and AML
Xu et al. Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
AU2016352912A1 (en) Modified immune cells and uses thereof
JP2025166001A (ja) 併用がん療法剤および方法
CN119816313A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
Elemam et al. CAR-NK/CAR-T cells: emerging immunotherapy of cancer
JP2020510681A (ja) 抗レナラーゼ抗体および抗pd−1抗体を用いる、がんを処置するための組成物および方法
Bogacz et al. Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors
US20240034788A1 (en) Abscopal therapy for cancer
Bieliński et al. Advancing Immunotherapy in Chronic Lymphocytic Leukemia
US20260132375A1 (en) Modified t cells and uses thereof
CA3009161C (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
WO2024148402A1 (en) A method of preparing cells for adoptive cell therapy
Nahas et al. Targeting CD20 in chronic lymphocytic leukemia
Nezhad et al. CAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Sun et al. Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma
He et al. Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of in vivo CAR-T platforms